Cyclo Therapeutics, Inc. (CYTH) 10-K Annual Report March 2023

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Mar. 15, 2023	Jun. 30, 2022
Document Information [Line Items]
Entity Central Index Key	0000922247
Entity Registrant Name	Cyclo Therapeutics, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	0-25466
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3029743
Entity Address, Address Line One	6714 NW 16th Street, Suite B
Entity Address, City or Town	Gainesville
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32653
City Area Code	386
Local Phone Number	418-8060
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 14,693,080
Entity Common Stock, Shares Outstanding		10,554,900
Auditor Firm ID	100
Auditor Name	WithumSmith+Brown, PC
Auditor Location	East Brunswick, New Jersey
Warrants To Purchase Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase Common Stock
Trading Symbol	CYTHW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $.0001 per share
Trading Symbol	CYTH
Security Exchange Name	NASDAQ

ChatGPT says Biotech Firm Develops Cyclodextrin-Based Treatments for Neurodegenerative Diseases.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/922247/000143774923007064/ctdh20221231_10k.htm

View differences made from one year to another to evaluate Cyclo Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Cyclo Therapeutics, Inc..

Continue

Assess how Cyclo Therapeutics, Inc.'s management team is paid from their Annual Proxy

Cyclo Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Other

Filter Subcategory:

All

Expense

Product

Earnings

Other

Inside Cyclo Therapeutics, Inc.'s 10-K Annual Report:

Financial - Expense Highlight
Office and other expenses decreased 3% to approximately $1,026,000 for 2022 from approximately $1,062,000 for 2021, primarily due to a decrease in insurance costs.

Financial - Expense Highlight
The increase in personnel expense is due an increase in employee bonuses based on achievements of targets approved by our Board of Directors, and an increase in the cost of employee benefits.
Other - Other Highlight
Preliminary data from our completed clinical studies suggest that Trappsol Cyclo clears toxic deposits of cholesterol and other lipids from cells, has a consistent pharmacokinetic profile peripherally, and crosses the blood-brain-barrier in individuals suffering from NPC, and results in neurological and neurocognitive benefits and other clinical improvements in NPC patients.
Revenue - Product Highlight
Revenue Recognition Revenues are recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.
Financial - Expense Highlight
If we have a material error in our estimate of the volatility of our stock, our expenses could be understated or overstated.
Financial - Expense
Research and development expenses decreased...Read more
Financial - Shares
In a concurrent private placement,...Read more
Revenue - Product
We recognize revenues following the...Read more
Revenue - Product
This percentage is a function...Read more
Financial - Expense
Our cost of goods sold...Read more
Financial - Expense
Personnel expenses increased 3% to...Read more
Financial - Earnings
When we experience short-term increases...Read more
Other - Other
The transaction price is recognized...Read more
Revenue - Product
Sales increased 150% to approximately...Read more
Revenue - Product
Trappsol? HPB Our sales of...Read more
Financial - Expense
Our cash decreased to approximately...Read more
Financial - Earnings
Therefore, our margins on these...Read more
Other - Other
Significant changes in assumptions and/or...Read more
Financial - Expense
The changes in research and...Read more
Financial - Shares
In addition, subsequent to the...Read more
Financial - Expense
We did not experience any...Read more
Revenue - Product
The transaction price, which includes...Read more
Other - Other
Valuation Allowance on Deferred Tax...Read more
Other - Other
Initial patient enrollment in the...Read more
Other - Other
There can be no guarantee...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Cyclo Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: CYTH
CIK: 922247
Form Type: 10-K Annual Report
Accession Number: 0001437749-23-007064
Submitted to the SEC: Fri Mar 17 2023 4:20:25 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Saturday, December 31, 2022
Industry: Industrial Organic Chemicals